Third-generation EGFR-TKI

DRUG2 trials

Sponsors

Hunan Province Tumor Hospital, First Affiliated Hospital of Guangxi Medical University

Conditions

Adjuvant TherapyNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Unknown Phase

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

RecruitingNCT04324164

Hunan Province Tumor HospitalNon-small Cell Lung Cancer

Start: 2020-03-24End: 2027-12-24Target: 800Updated: 2025-01-27

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

Not yet recruitingNCT07686185

First Affiliated Hospital of Guangxi Medical UniversityAdjuvant Therapy, Non-Small Cell Lung Cancer

Start: 2026-09-01End: 2032-12-31Target: 500Updated: 2026-07-07